Gilead Sciences Inc
NASDAQ: GILD
$83.94
+$0.04 (+0.0%)
Closing Price on September 20, 2024
GILD Articles
Tuesday's top analyst upgrades and downgrades included Beyond Meat, BioNTech, Comcast, DraftKings, Expedia, Gap, Gilead Sciences, Hess, Lululemon Athletica, Newmont and Royal Gold.
Published:
The April 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
Gilead Sciences took another big step forward in its treatment for COVID-19 on Friday when a Japanese regulatory body approved that treatment.
Published:
Monday's top analyst upgrades and downgrades included Amazon.com, American Airlines, American Express, Beyond Meat, Caterpillar, Clorox, eBay, Gilead Sciences, Twitter, Verizon Communications and...
Published:
The April 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Monday's top analyst upgrades and downgrades included AbbVie, American Electric Power, ANGI Homeservices, DuPont, GileadSciences, Microsoft, Peloton Interactive, Shopify, Trivago and Walt Disney.
Published:
While the COVID-19 pandemic wrecked the stock market and the economy, the recent rally in the stock market has been at a time when the economic news is only getting worse and as coronavirus news...
Published:
These five top biotech companies range from a large-cap leader with a potential coronavirus treatment to a small-cap company with massive upside potential.
Published:
The March 31 short interest data has been compared with the previous report, and short interest in these selected biotech stocks shrank.
Published:
Tuesday's top analyst upgrades and downgrades included BHP, Electronic Arts, Gilead Sciences, Immunomedics, KeyCorp, Peloton Interactive, Shopify, Sunnova Energy, Take-Two Interactive and Walt Disney.
Published:
These five top companies have large troves of cash and very little debt. Their stocks make sense for long-term growth investors who have an eye on recovery down the road.
Published:
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
Published:
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Published:
U.S. consumer confidence continues to decline, but the slide has slowed. On Sunday, the FDA and the Department of Health and Human Services okayed two drugs for use in the fight against COVID-19.
Published:
The March 13 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published: